Researchers said that a U.K. study of using different Covid-19 vaccines in two-dose inoculations is now expanded to include vaccines made by Moderna Inc (NASDAQ: MRNA) and Novavax...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs April 13)Bio-Techne Corporation (NASDAQ:...
It was a week full of strong reports to kick off earnings season, as well as encouraging economic data to kick off an economic boom. As a result, each of the major indices gained...
A strong late-day rally on Friday made an already solid week even better, complete with new closing highs for a couple major indices and some positive momentum heading into the...
Wall Street delivered a satisfactory performance in March. Accelerated coronavirus vaccine rollout, unprecedented fiscal stimulus support along with the Fed’s decision to...
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).